Sabby Management Cut Its Aldeyra Therapeutics (ALDX) Holding; Nordstrom, Inc. (JWN) Had 8 Analysts Last Week

October 31, 2017 - By Peter Erickson

Sabby Management Llc decreased Aldeyra Therapeutics Inc. (ALDX) stake by 45.61% reported in 2017Q2 SEC filing. Sabby Management Llc sold 81,923 shares as Aldeyra Therapeutics Inc. (ALDX)’s stock declined 12.75%. The Sabby Management Llc holds 97,704 shares with $454,000 value, down from 179,627 last quarter. Aldeyra Therapeutics Inc. now has $117.18 million valuation. The stock declined 2.30% or $0.15 reaching $6.16 per share. About 98,308 shares traded. Aldeyra Therapeutics Inc (NASDAQ:ALDX) has declined 18.94% since October 31, 2016 and is downtrending. It has underperformed by 35.64% the S&P500.

Among 29 analysts covering Nordstrom Inc. (NYSE:JWN), 8 have Buy rating, 6 Sell and 15 Hold. Therefore 28% are positive. Nordstrom Inc. had 91 analyst reports since August 14, 2015 according to SRatingsIntel. JP Morgan downgraded the shares of JWN in report on Friday, December 16 to “Underweight” rating. The stock of Nordstrom, Inc. (NYSE:JWN) earned “Buy” rating by KeyBanc Capital Markets on Wednesday, October 11. The stock of Nordstrom, Inc. (NYSE:JWN) has “Buy” rating given on Friday, November 11 by Maxim Group. The stock has “Neutral” rating by Goldman Sachs on Friday, October 23. The firm earned “Outperform” rating on Wednesday, January 18 by Credit Suisse. The rating was upgraded by Northcoast on Monday, May 16 to “Neutral”. The firm earned “Hold” rating on Monday, October 31 by Deutsche Bank. The stock of Nordstrom, Inc. (NYSE:JWN) earned “Neutral” rating by Citigroup on Tuesday, January 5. As per Friday, February 10, the company rating was initiated by Susquehanna. As per Thursday, September 14, the company rating was maintained by Piper Jaffray. See Nordstrom, Inc. (NYSE:JWN) latest ratings:

18/10/2017 Broker: Piper Jaffray Rating: Hold New Target: $42.0 Maintain
11/10/2017 Broker: KeyBanc Capital Markets Rating: Buy New Target: $55.0 Maintain
03/10/2017 Broker: RBC Capital Markets Rating: Hold New Target: $45.0 Maintain
14/09/2017 Broker: Piper Jaffray Rating: Hold New Target: $42.0 Maintain
13/09/2017 Broker: BMO Capital Markets Rating: Hold New Target: $48.0 Maintain
13/09/2017 Broker: Gordon Haskett Old Rating: Accumulate New Rating: Hold Old Target: $54 Downgrade
30/08/2017 Broker: KeyBanc Capital Markets Rating: Buy New Target: $55.0 Maintain
29/08/2017 Broker: RBC Capital Markets Rating: Hold New Target: $45.0 Maintain
11/08/2017 Broker: Robert W. Baird Rating: Hold New Target: $50.0000
11/08/2017 Broker: Cowen & Co Rating: Buy New Target: $49.0000 Maintain

Analysts await Aldeyra Therapeutics Inc (NASDAQ:ALDX) to report earnings on November, 13. They expect $-0.42 earnings per share, down 10.53% or $0.04 from last year’s $-0.38 per share. After $-0.35 actual earnings per share reported by Aldeyra Therapeutics Inc for the previous quarter, Wall Street now forecasts 20.00% negative EPS growth.

Sabby Management Llc increased Sarepta Therapeutics Inc (Call) stake by 1,597 shares to 5,646 valued at $19.03M in 2017Q2. It also upped Merck & Co Inc (Put) stake by 3,704 shares and now owns 7,031 shares. Cigna Corp (Call) was raised too.

Investors sentiment decreased to 1.67 in Q2 2017. Its down 0.66, from 2.33 in 2017Q1. It dropped, as 3 investors sold ALDX shares while 6 reduced holdings. 7 funds opened positions while 8 raised stakes. 7.44 million shares or 2.21% less from 7.60 million shares in 2017Q1 were reported. Northern Corp, a Illinois-based fund reported 14,999 shares. Hikari Power Limited owns 107,858 shares for 0.07% of their portfolio. Vanguard Group Incorporated reported 304,633 shares or 0% of all its holdings. Fmr Limited Liability Company has invested 0% of its portfolio in Aldeyra Therapeutics Inc (NASDAQ:ALDX). 683 Cap Management Limited Liability Corp accumulated 525,093 shares or 0.36% of the stock. Perceptive Lc accumulated 0.68% or 2.89 million shares. Moreover, Weiss Multi has 0.01% invested in Aldeyra Therapeutics Inc (NASDAQ:ALDX). Geode Cap Management Ltd Liability Com, a Massachusetts-based fund reported 57,854 shares. Moreover, Knoll Cap Lp has 0.77% invested in Aldeyra Therapeutics Inc (NASDAQ:ALDX) for 124,096 shares. Tower Rech Capital Limited (Trc) has invested 0% in Aldeyra Therapeutics Inc (NASDAQ:ALDX). Millennium Mngmt accumulated 100,500 shares. Morgan Stanley reported 0% in Aldeyra Therapeutics Inc (NASDAQ:ALDX). Pennsylvania-based Sei has invested 0% in Aldeyra Therapeutics Inc (NASDAQ:ALDX). Sphera Funds Mgmt Limited, Israel-based fund reported 875,931 shares. Blackrock accumulated 0% or 39,544 shares.

Among 5 analysts covering Aldeyra Therapeutics Inc (NASDAQ:ALDX), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Aldeyra Therapeutics Inc had 11 analyst reports since August 13, 2015 according to SRatingsIntel. The stock of Aldeyra Therapeutics Inc (NASDAQ:ALDX) has “Buy” rating given on Friday, July 1 by Stifel Nicolaus. The company was maintained on Wednesday, September 13 by Canaccord Genuity. The stock of Aldeyra Therapeutics Inc (NASDAQ:ALDX) earned “Buy” rating by Cantor Fitzgerald on Tuesday, October 24. H.C. Wainwright maintained it with “Buy” rating and $1800 target in Wednesday, August 9 report. The company was maintained on Wednesday, August 9 by Cowen & Co. The stock of Aldeyra Therapeutics Inc (NASDAQ:ALDX) has “Outperform” rating given on Tuesday, September 8 by Cowen & Co. The firm has “Buy” rating by H.C. Wainwright given on Monday, September 26. The stock of Aldeyra Therapeutics Inc (NASDAQ:ALDX) earned “Buy” rating by Canaccord Genuity on Wednesday, June 14. The rating was maintained by H.C. Wainwright on Thursday, June 15 with “Buy”. Cowen & Co maintained it with “Buy” rating and $14.0 target in Thursday, September 14 report.

The stock decreased 0.87% or $0.35 during the last trading session, reaching $39.65. About 2.14M shares traded. Nordstrom, Inc. (NYSE:JWN) has risen 9.86% since October 31, 2016 and is uptrending. It has underperformed by 6.84% the S&P500.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Peter Erickson




Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: